Treatment and Prevention of HPV-Associated Skin Tumors by HPV Vaccination
HPV-associated dermatological diseases include benign lesions like cutaneous warts and external genital warts. In addition, HPV infection is associated with the development of epithelial skin cancers, in particular cutaneous squamous cell carcinoma (cSCC). In contrast to anogenital and oropharyngeal...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/12/12/1439 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846102440910258176 |
|---|---|
| author | Thomas Meyer Eggert Stockfleth |
| author_facet | Thomas Meyer Eggert Stockfleth |
| author_sort | Thomas Meyer |
| collection | DOAJ |
| description | HPV-associated dermatological diseases include benign lesions like cutaneous warts and external genital warts. In addition, HPV infection is associated with the development of epithelial skin cancers, in particular cutaneous squamous cell carcinoma (cSCC). In contrast to anogenital and oropharyngeal cancers caused by mucosal HPV types of genus alpha papillomavirus, cSCC-associated HPV types belong to the genus beta papillomavirus. Currently available HPV vaccines that target mucosal HPV types associated with anogenital cancer and genital warts are type-specific and provide no cross-protection against beta HPV. When implementing vaccination to beta HPV to prevent skin tumors, it must be considered that acquisition of these HPV types occurs early in childhood and that the risk for cSCC increases with growing age and decreasing immune surveillance. Thus, individuals considered for beta HPV vaccination usually have pre-existing infection and are largely immunocompromised. On the other hand, worldwide increasing incidence rates of epithelial skin cancer reflect an urgent need for skin cancer prevention measures. Based on the pathogenic involvement of beta HPV, vaccination may represent a promising prevention strategy. Indeed, various procedures of prophylactic and therapeutic vaccination have been developed, and some of them have shown efficiency in animal models. Thus far, however, none of these vaccine candidates has been approved for application in humans. |
| format | Article |
| id | doaj-art-9be23e6b4c1a429bb025d8ae709d0399 |
| institution | Kabale University |
| issn | 2076-393X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-9be23e6b4c1a429bb025d8ae709d03992024-12-27T14:58:15ZengMDPI AGVaccines2076-393X2024-12-011212143910.3390/vaccines12121439Treatment and Prevention of HPV-Associated Skin Tumors by HPV VaccinationThomas Meyer0Eggert Stockfleth1Department of Dermatology, St. Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, GermanyDepartment of Dermatology, St. Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, GermanyHPV-associated dermatological diseases include benign lesions like cutaneous warts and external genital warts. In addition, HPV infection is associated with the development of epithelial skin cancers, in particular cutaneous squamous cell carcinoma (cSCC). In contrast to anogenital and oropharyngeal cancers caused by mucosal HPV types of genus alpha papillomavirus, cSCC-associated HPV types belong to the genus beta papillomavirus. Currently available HPV vaccines that target mucosal HPV types associated with anogenital cancer and genital warts are type-specific and provide no cross-protection against beta HPV. When implementing vaccination to beta HPV to prevent skin tumors, it must be considered that acquisition of these HPV types occurs early in childhood and that the risk for cSCC increases with growing age and decreasing immune surveillance. Thus, individuals considered for beta HPV vaccination usually have pre-existing infection and are largely immunocompromised. On the other hand, worldwide increasing incidence rates of epithelial skin cancer reflect an urgent need for skin cancer prevention measures. Based on the pathogenic involvement of beta HPV, vaccination may represent a promising prevention strategy. Indeed, various procedures of prophylactic and therapeutic vaccination have been developed, and some of them have shown efficiency in animal models. Thus far, however, none of these vaccine candidates has been approved for application in humans.https://www.mdpi.com/2076-393X/12/12/1439papillomavirusskin cancergenital wartscutaneous wartsoncogeneskin microbiome |
| spellingShingle | Thomas Meyer Eggert Stockfleth Treatment and Prevention of HPV-Associated Skin Tumors by HPV Vaccination Vaccines papillomavirus skin cancer genital warts cutaneous warts oncogene skin microbiome |
| title | Treatment and Prevention of HPV-Associated Skin Tumors by HPV Vaccination |
| title_full | Treatment and Prevention of HPV-Associated Skin Tumors by HPV Vaccination |
| title_fullStr | Treatment and Prevention of HPV-Associated Skin Tumors by HPV Vaccination |
| title_full_unstemmed | Treatment and Prevention of HPV-Associated Skin Tumors by HPV Vaccination |
| title_short | Treatment and Prevention of HPV-Associated Skin Tumors by HPV Vaccination |
| title_sort | treatment and prevention of hpv associated skin tumors by hpv vaccination |
| topic | papillomavirus skin cancer genital warts cutaneous warts oncogene skin microbiome |
| url | https://www.mdpi.com/2076-393X/12/12/1439 |
| work_keys_str_mv | AT thomasmeyer treatmentandpreventionofhpvassociatedskintumorsbyhpvvaccination AT eggertstockfleth treatmentandpreventionofhpvassociatedskintumorsbyhpvvaccination |